Clinical Trial Update: A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion and posting of Phase 3 results for a six-month study of once-daily ciclesonide HFA nasal aerosol in the treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• ciclesonide HFA nasal aerosol (ciclesonide)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Perennial Allergic Rhinitis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-11